SNZOZ MED-MED SP. Z O.O
- Address
- lock Available on a paid plan
SNZOZ MED-MED SP. Z O.O - Respiratory Medicine Research Center
SNZOZ MED-MED SP. Z O.O is a specialized clinical research facility focused on respiratory medicine and pulmonary therapeutics. The center has established expertise in conducting complex pharmaceutical trials for moderate to severe asthma, with particular emphasis on evaluating novel inhaled medication delivery systems and propellant formulations.
- Advanced asthma management trials (GINA Step 4 and Step 5 treatment protocols)
- Pressurized metered-dose inhaler (pMDI) safety and efficacy studies
- Comparative propellant formulation research (HFA-152a vs HFA-134a)
- Bronchoconstriction potential assessment and respiratory safety monitoring
The research center demonstrates proficiency in conducting multicentre, double-blind, active-controlled trials that evaluate the safety profiles of triple-combination respiratory medications. Their capabilities include sophisticated pulmonary function testing, bronchodilator response assessments, and comprehensive safety monitoring for patients with controlled asthma requiring high-intensity maintenance therapy according to Global Initiative for Asthma (GINA) Guidelines.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 930 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in SNZOZ MED-MED SP. Z O.O
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Safety Evaluation of CHF5993 pMDI Formulated with HFA-152a Versus HFA-134a in Moderate to Severe Asthma Patients | Chiesi Farmaceutici S.p.A. | Phase III | Not Recruiting | Jan 2024 | Feb 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Beclometasone Dipropionate Anhydrous | 1 | Unknown | 2024-01-15 | 2024-01-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.